In a study that focused on the use of AG‐120 (ivosidenib) in 73 patients with IDH1‐mutated ICC, 5% of the patients showed partial response to the diagnosis and 56% experienced stable disease, and the 6‐month PFS rate was 40%.60 Here, IDH1 is linked to intrahepatic cholangiocarcinoma.